Vimarsana
Biggest News Aggregation in the World

Kea Technologies News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Kea Technologies. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Kea Technologies Today - Breaking & Trending Today

Mauna Kea Technologies Announces 9 Presentations Demonstrating the Clinical Value of Cellvizio® at Digestive Disease Week® 2024 - Vimarsana News

Mauna Kea Technologies Announces 9 Presentations Demonstrating the Clinical Value of Cellvizio® at Digestive Disease Week® 2024

AI, pancreatic cancer and food intolerance headline wide range of Cellvizio abstracts at gastroenterology’s largest international meeting ...

Loan deferment gives Mauna Kea more breathing space - Vimarsana News

Loan deferment gives Mauna Kea more breathing space

Developer of 'Cellvizio' endomicroscopy platform restructures repayment terms; opens lung cancer diagnostics center in France.

Source: optics.org
Mauna Kea Technologies: Publication of the 2023 Annual Financial Report - Vimarsana News

Mauna Kea Technologies: Publication of the 2023 Annual Financial Report

Regulatory News: Mauna Kea Technologies , inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy platform, today announced that it has published its...

Mauna Kea Technologies : Publication of the 2023 Annual Financial Report - Vimarsana News

Mauna Kea Technologies : Publication of the 2023 Annual Financial Report

Publication of the 2023 Annual Financial Report Paris and Boston, April 30, 2024 - 5:45 p.m. CEST - Mauna Kea Technologies , inventor of...

Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio® in Lung Cancer Diagnostics - Vimarsana News

Mauna Kea Technologies Announces the Opening of a French Center of Excellence for the Use of Cellvizio® in Lung Cancer Diagnostics

Cellvizio utilization continues to expand globally in established and emerging clinical indications ...